<DOC>
	<DOC>NCT00914433</DOC>
	<brief_summary>This study will look at the safety and tolerability of TPI 1100 in healthy volunteers and look at pharmacodynamic (PD) effect on mRNA expression of PDE 4B/D &amp; 7A in blood and in sputum.</brief_summary>
	<brief_title>Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Inhaled TPI 1100 in Healthy Volunteers</brief_title>
	<detailed_description>Study was not initiated and terminated before start-up.</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<criteria>Healthy, male or female volunteers aged 18 to 55 years inclusive Screening/baseline FEV1 greater than 90% predicted, Body mass index (BMI) of 19 to 28 inclusive, Clinical laboratory values and/or vital signs within normal reference ranges or not considered clinically significant by the Investigator Airways or systemic conditions that might affect respiratory function, including but not limited to clinically significant cardiac problems, Breastfeeding or pregnancy, Positive tests for smoking tobacco, alcohol, hepatitis Bsurface antigen, hepatitis C antibody, and HIV at screening, History of serious adverse reaction to any drugs,</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>COPD</keyword>
</DOC>